Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma

Published:2015-10-06 Issue:5 Volume:30 Page:1211-1214
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Ladetto M,Ferrero S,Drandi D,Festuccia M,Patriarca F,Mordini N,Cena S,Benedetto R,Guarona G,Ferrando F,Brunello L,Ghione P,Boccasavia V,Fanin R,Omedè P,Giaccone L,Palumbo A,Passera R,Boccadoro M,Bruno B

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015269.pdf

Reference15 articles.

1. Festuccia M, Martino M, Ferrando F, Messica G, Moscato T, Fedele R et al. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. Expert Opin Biol Ther 2015; 15: 857–872.

2. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 1927–1929.

3. Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 398–404.

4. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454.

5. Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11: 1793–1798.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study;Haematologica;2023-11-09

2. IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma;Scientific Reports;2023-05-26

3. Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis;OncoImmunology;2022-11-01

4. Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma;Hemato;2021-02-20

5. Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?;Panminerva Medica;2021-01